You just read:

Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

News provided by

Blueprint Medicines Corporation

Jan 09, 2020, 15:52 ET